Replies to post #404391 on Elite Pharmaceuticals Inc (ELTP)

[namtae]

I think the CEO may have been waiting for confirmation you sold everything at .15 before announcing the needle movers

Fortunately, you did sell it all so the needle movers are on their way

[NASDAQ2020]

This shows when they were filed with FDA:

X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 15. Vigabatrin Approval $233 Million
X 16. Pyros Vigabatrin -settle VigPoder trade mark challenge then LAUNCH
X 17. Generic Methotrexate Approval- Antimetabolite $42 Million
X 18. $50+ million in yearly revenues
X 19. Lowest PE ratio for OTC Healthcare sector
X 20. Become the ONLY company showing rapid growth on the OTC while being profitable
__21. Generate revenues over $20 million/quarter
X.22. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__23. Double output of manufacturing and packaging facilities
__24. Generic OxyContin Approval FIRST TO FILE Aug 17, 2023 $720 Million
__25. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__26. Launch Tylenol with codeine $45 Million
__27. Launch generic Norco - hydrocodone acetaminophen IMS $477 Million
__28. Launch generic Percocet - oxycodone acetaminophen IMS $500 Million
__29. Launch generic Dolophine - methadone HCL tablets IMS $30 Million
__30. European distribution - Dexcel partnership approval by Israeli Health
__31. Full ownership of Adderall IR $ 335 Million
__32. Full ownership of Adderall XR $ 1.56 Billion
__33. Generic Concerta- $1.2 BILLION FDA submission
__34. $100 million in yearly revenue
__35. Generic Vyvanse Approval and Launch
__36. $200 million in yearly revenue
__37. Deep pocket partner for SequestOx
__38. Patented Unique ADF (w/o naltrexone) drug C in SequestOx trial
__39. Mikah ANDA(s)
__40. Undisclosed ANDAs/NDAs
__41. Generic Concerta Approval and Launch
__42. DollarLand PPS
__43. Big Pharma bid
__44. UpList to the NASDAQ Exchange
__45. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__46. Vegas Baby !!!!!!!